Abstract
The clinical manifestations of thromboembolic disease were first described by Hippocrates (460–370 BC). In the 17th and 18th centuries, the study of human anatomy in health and disease led to greater understanding of the pathophysiology of thrombotic disease and the first treatments for it. Modern approaches to treatment of arterial and venous thromboembolism emerged in the late 19th and 20th centuries with the identification of acetylsalicylic acid, heparin, and warfarin. The last 50 years has witnessed the development of evidence-based antithrombotic therapy management and targeted therapeutics including glycoprotein IIb/IIIa inhibitors and direct oral anticoagulants directed against thrombin and factor Xa. The ever increasing number of therapeutic agents and procedures for thromboembolic disease presents a challenge for healthcare providers to stay abreast of the latest developments in antithrombotic therapy. We hope this book will be a valuable resource for practitioners caring for patients with thrombotic disease.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Pearce JM. Johann Jakob Wepfer (1620-95) and cerebral hemorrhage. J Neurol Neurosurg Psychiatry. 1997;62:387.
de Saint Pathus G. La vie et les Miracles de Saint Louis. Paris: Biblioth eque National de France.1271;1330–50.
Galanaud J-P, Laroche J-P, Righini M. The history and historical treatments of deep vein thrombosis. J Thromb Haemost. 2013;11:402–11.
Anning S. The historical aspects. In: Dodd H, Cockett F, editors. The pathology and surgery of the lower limbs. 2nd ed. Edinburgh: Churchill Livingston; 1976. p. 3–17.
Hunter H. Observations on the inflammation of the internal coats of veins. Trans Soc Improv Med Chir Knowledge. 1793;1:18–41.
Magner L. A history of medicine. New York: Marcel Dekker; 1992. 393 p.
Howell H, Holt E. Two new factors in blood coagulation - heparin and pro-antithrombin. Am J Phys. 1918;47:328–41.
Murray D, Jacques L, Perrett T, Best C. Heparin and the thrombosis of veins following injury. Surgery. 1937;2:163–87.
Wardrop D, Keeling D. The story of the discovery of heparin and warfarin. Br J Haematol. 2008;474:757–63.
Roderick L. The pathology of sweet clover disease in cattle. J Am Vet Med Assoc. 1929;74:314–25.
Roderick L. A problem in the coagulation of blood: “sweet clover disease of cattle”. Am J Phys. 1931;96:413–25.
Schofield F. The cause of a new disease in cattle stimulating hemorrhagic septicaemia and blackleg. J Am Vet Med Assoc. 1924;64:553–75.
Whitlon D, Sadowski J, Suttie J. Mechanisms of coumarin action: significance of vitamin K epoxide reductase inhibition. Biochemistry. 1978;17(8):1371–7.
Stahmann M, Huebner C, Link K. Studies on the hemorrhagic sweet clover disease. J Biol Chem. 1941;138:513–27.
Wright I. Experience with anticoagulants. Circulation. 1959;19:110–3.
Prandoni A, Wright I. The anti-coagulants, heparin and the dicoumarin 3,3′ methylene-bis (4-hydroxycoumarin). N Y Acad Med. 1942;18:433.
Link K. The discovery of dicoumarol and its sequels. Circulation. 1959;19:97–107.
Makaryus JN, Halperin JL, Lau JF. Oral anticoagulants in the management of venous thromboembolism. Nat Rev Cardiol. 2013;10(7):397–409.
Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuunemann HJ. American college of chest physicians Antithrombotic T, et al. executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):7S–47S.
Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315–52.
Ansell JE. Management of venous thromboembolism: clinical guidance from the Anticoagulation Forum. J Thromb Thrombolysis. 2016;41(1):1–2.
Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galie N, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014;35(43):3033–69, 69a-69k.
Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17(10):1467–507.
Cohen H, Arachchillage DR, Middeldorp S, Beyer-Westendorf J, Abdul-Kadir R. Management of direct oral anticoagulants in women of childbearing potential: guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14(8):1673–6.
Martin K, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14(6):1308–13.
Ruff CT, Ansell JE, Becker RC, Benjamin EJ, Deicicchi DJ, Mark Estes NA, et al. North American Thrombosis Forum, AF action initiative consensus document. Am J Med. 2016;129(5 Suppl):S1–S29.
January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):e199–267.
Task Force Members, Lip GY, Windecker S, Huber K, Kirchhof P, Marin F, Document Reviewers, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J. 2014;35(45):3155–79.
Verma A, Cairns JA, Mitchell LB, Macle L, Stiell IG, Gladstone D, et al. 2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. Can J Cardiol. 2014;30(10):1114–30.
Sticherling C, Marin F, Birnie D, Boriani G, Calkins H, Dan GA, et al. Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS). Europace. 2015;17(8):1197–214.
Heidenreich PA, Solis P, Estes NA 3rd, Fonarow GC, Jurgens CY, Marine JE, et al. 2016 ACC/AHA clinical performance and quality measures for adults with atrial fibrillation or atrial flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. J Am Coll Cardiol. 2016;68(5):525–68.
Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18(11):1609–78.
Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, et al. American Society of Clinical Oncology. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline update 2014. J Clin Oncol. 2015;33(6):654–6.
Streiff MB, Holmstrom B, Ashrani A, Bockenstedt PL, Chesney C, Eby C, et al. Cancer-associated venous thromboembolic disease, version 1.2015. J Natl Compr Cancer Netw. 2015;13(9):1079–95.
Anticoagulation forum centers of excellence. Website www.excellence.acforum.org.
Anticoagulation toolkit on anticoagulation forum of excellence. Website www.anticoagulationtoolkit.org.
Shehab N, Lovegrove MC, Geller AI, Rose KO, Weidle NJ, Budnitz DS. US emergency department visits for outpatient adverse drug events, 2013–2014. JAMA. 2016;316(20):2115–25.
Barnes GD, Nallamothu BK, Sales AE, Froehlich JB. Reimagining anticoagulation clinics in the era of direct oral anticoagulants. Circ Cardiovasc Qual Outcomes. 2016;9(2):182–5.
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Lau, J.F., Barnes, G.D., Streiff, M.B. (2018). Introduction. In: Lau, J., Barnes, G., Streiff, M. (eds) Anticoagulation Therapy . Springer, Cham. https://doi.org/10.1007/978-3-319-73709-6_1
Download citation
DOI: https://doi.org/10.1007/978-3-319-73709-6_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-73708-9
Online ISBN: 978-3-319-73709-6
eBook Packages: MedicineMedicine (R0)